TY - JOUR
T1 - Pituitary Neoplasm Nomenclature Workshop
T2 - Does Adenoma Stand the Test of Time?
AU - Ho, Ken
AU - Fleseriu, Maria
AU - Kaiser, Ursula
AU - Salvatori, Roberto
AU - Brue, Thierry
AU - Lopes, M. Beatriz
AU - Kunz, Pamela
AU - Molitch, Mark
AU - Camper, Sally A.
AU - Gadelha, Mônica
AU - Syro, Luis V.
AU - Laws, Edward
AU - Reincke, Martin
AU - Nishioka, Hiroshi
AU - Grossman, Ashley
AU - Barkan, Ariel
AU - Casanueva, Felipe
AU - Wass, John
AU - Mamelak, Adam
AU - Katznelson, Laurence
AU - Van Der Lely, Aart J.
AU - Radovick, Sally
AU - Bidlingmaier, Martin
AU - Boguszewski, Margaret
AU - Bollerslev, Jens
AU - Hoffman, Andrew R.
AU - Oyesiku, Nelson
AU - Raverot, Gerald
AU - Ben-Shlomo, Anat
AU - Fowkes, Rob
AU - Shimon, Ilan
AU - Fukuoka, Hidenori
AU - Pereira, Alberto M.
AU - Greenman, Yona
AU - Heaney, Anthony P.
AU - Gurnell, Mark
AU - Johannsson, Gudmundur
AU - Osamura, Robert Y.
AU - Buchfelder, Michael
AU - Zatelli, Maria Chiara
AU - Korbonits, Marta
AU - Chanson, Philippe
AU - Biermasz, Nienke
AU - Clemmons, David R.
AU - Karavitaki, Niki
AU - Bronstein, Marcello D.
AU - Trainer, Peter
AU - Melmed, Shlomo
N1 - Funding Information:
Supported by unrestricted educational grants to the Pituitary Society from Chiasma, Inc., Corcept Therapeutics, Ipsen Biopharmaceuticals, Novo Nordisk, Pfizer Inc., Strongbridge Biopharma, and Tiburio Therapeutics. Funding sources had no role in data collection, analysis, and interpretation, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of the Endocrine Society.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.
AB - The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written précis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.
UR - http://www.scopus.com/inward/record.url?scp=85119515238&partnerID=8YFLogxK
U2 - 10.1210/jendso/bvaa205
DO - 10.1210/jendso/bvaa205
M3 - Article
C2 - 33604494
AN - SCOPUS:85119515238
SN - 2472-1972
VL - 5
JO - Journal of the Endocrine Society
JF - Journal of the Endocrine Society
IS - 3
M1 - bvaa205
ER -
